We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
CLEU | China Liberal Education Holdings Ltd | 3.1505 | 1.13 | 55.97% | 17,884,861 |
HUDA | Hudson Acquisition I Corporation | 16.6999 | 5.75 | 52.51% | 635,962 |
VERO | Venus Concept Inc | 0.893101 | 0.3064 | 52.22% | 64,786,516 |
HRYU | Hanryu Holdings Inc | 0.5047 | 0.1456 | 40.55% | 2,832,338 |
HUDAU | Hudson Acquisition I Corporation | 15.77 | 3.66 | 30.22% | 3,765 |
AONC | American Oncology Network Inc | 2.20 | 0.50 | 29.41% | 5,187,789 |
XTKG | X3 Holdings Company Ltd | 0.76 | 0.17 | 28.81% | 843,545 |
LFLY | Leafly Holdings Inc | 2.5601 | 0.5401 | 26.74% | 30,936,401 |
CMLS | Cumulus Media Inc | 2.45 | 0.50 | 25.64% | 155,055 |
SISI | Shineco Inc | 2.77 | 0.49 | 21.49% | 269,304 |
VIRC | Virco Manufacturing Company | 13.15 | 2.29 | 21.09% | 514,129 |
JERUSALEM, June 7, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that on June 5, 2024, it received formal notification from the Listing Qualification Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") that the Company has regained compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule").
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference in Glasgow, Scotland.
Semtech Corporation (“Semtech” or the “Company”) (Nasdaq: SMTC), a high-performance semiconductor, IoT systems, and connectivity service provider, today announced the appointment of Dr. Hong Q. Hou, a current member of the Semtech Board of Directors, as President and Chief Executive Officer, effective June 6, 2024. Dr. Hou’s appointment follows Paul H. Pickle’s departure as President and Chief Executive Officer.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
NWBO | NorthWest Biotherapeutics Inc | 189 | |
LWLG | Lightwave Logic Inc | 115 | |
COOP | Mr Cooper Group Inc | 12 | |
4 | NSAV | NSAV Holding Inc | 47 |
5 | SPZI | SPOOZ Inc | 48 |
6 | RDGL | Vivos Inc | 6 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 69,672.24 | 18.18 | 0.03% | 1.37T | 1,226,887,782 |
ETH | Ethereum | 3,688.18 | -17.94 | -0.48% | 443.35B | 815,426,700 |
BNB | Binance Coin | 670.35 | -2.71 | -0.40% | 106.07B | 164,129,370 |
USDT | Tether USD | 0.99974 | -0.00012 | -0.01% | 97.82B | 97,644,253 |
SOL | Solana | 160.56 | -1.63 | -1.00% | 70.95B | 412,403,958 |
STETH | stETH | 3,673.64 | -18.76 | -0.51% | 36.03B | 2,055,613 |
USDC | USD Coin | 0.9997 | -0.0002 | -0.02% | 28.07B | 226,962,617 |
XRP | Ripple | 0.4992 | 0.0005 | 0.10% | 27.22B | 87,610,828 |
TONCOIN | Wrapped TON Coin | 7.09 | -0.018881 | -0.27% | 24.7B | 75,969,265 |
DOGE | Dogecoin | 0.14631 | -0.00049 | -0.33% | 20.93B | 138,043,889 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions